Outlook Therapeutics News and Activities

Outlook Therapeutics is a company listed under the stock ticker OTLK (US).

View the org chart displaying its 27 main executives

Most searched biographies at Outlook Therapeutics

• Bob Jahr, Chief Executive Officer
• Randy Thurman, Director
• Julian Gangolli, Director

Popular executive movements at Outlook Therapeutics

• Laura Cantrell has joined the company as Vice President of Corporate Strategy and Business Development  (posted on January 7 2026).
• Jeff Evanson, Chief Commercial Officer, has left the company  (posted on October 1 2025).

Create your alert
to follow the executive moves at Outlook Therapeutics.

Outlook Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Outlook Therapeutics

• Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
• Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital - Outlook Therapeutics, Inc.
• Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
• Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
• Outlook Therapeutics to Present at Two Upcoming Investor Conferences - Outlook Therapeutics, Inc.
• Press Releases - Outlook Therapeutics, Inc.
• Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1 - Outlook Therapeutics, Inc.
• View more press releases Close

Social media about Outlook Therapeutics

• Outlook Therapeutics on Wikipedia, Google News & Yahoo Finance
• Outlook Therapeutics on LinkedIn, X (Twitter) & YouTube